›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:AVENIO ctDNA Targeted Kit
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
RocheType:
Laboratory Developed Test
Related tests:
3ms
MUTATIONAL ANALYSIS OF CIRCULATING TUMOUR DNA (CTDNA) IN HIGH GRADE SEROUS OVARIAN CANCER (HGSC) USING CANCER PERSONALISED PROFILING BY DEEP SEQUENCING (CAPP-SEQ) (IGCS 2024)
80% of patients had detectable ctDNA at baseline (mutant DNA copies/ml) with somatic mutations found in TP53, BRCA1, KRAS, NRAS, MET and ERBB2 genes. CNVs were found in EGFR and MET. 69% of all plasmas were ctDNA+.
Tumor mutational burden • BRCA Biomarker • Circulating tumor DNA
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA1 (Breast cancer 1, early onset)
|
TP53 mutation • KRAS mutation • BRCA1 mutation • NRAS mutation • MET mutation
|
AVENIO ctDNA Targeted Kit
1year
OSIRIS: Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed. (clinicaltrials.gov)
P=N/A; Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2023 --> Aug 2024
Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
AVENIO ctDNA Targeted Kit
|
Tagrisso (osimertinib)
Share
